Okay, let's tackle this question about the best drug for chronic gout in a patient with renal impairment. First, I need to recall the main drugs used for chronic gout. The primary medications are urate-lowering therapies like allopurinol, febuxostat, and probenecid. But wait, the patient has renal impairment, so I need to consider how each drug is metabolized and excreted.

Allopurinol is a xanthine oxidase inhibitor that reduces uric acid production. It's primarily metabolized by the liver and excreted by the kidneys. But in renal impairment, the dosage needs adjustment because decreased excretion can lead to accumulation. However, it's still used with caution in such patients.

Febuxostat is another xanthine oxidase inhibitor but is metabolized hepatically and excreted in both feces and urine. Since it's less dependent on renal function, it might be a better choice for those with renal issues. I remember that febuxostat has a lower risk of toxicity in renal impairment compared to allopurinol.

Probenecid is a uricosuric agent that increases uric acid excretion through the kidneys. However, in renal impairment, the kidneys can't excrete uric acid effectively, making probenecid less effective and potentially harmful. So, probenecid is contraindicated in renal dysfunction.

Lesinurad is another uricosuric agent, but it's usually used in combination with xanthine oxidase inhibitors. However, similar to probenecid, its efficacy depends on renal function, so it's not ideal for significant renal impairment.

So, considering all this, the best option for renal impairment would be febuxostat. It's metabolized and excreted without heavy reliance on the kidneys, making it safer in such patients. Allopurinol requires dose adjustment, but febuxostat is preferred when renal function is compromised. Also, the risk of hypersensitivity reactions with allopurinol is higher in patients with renal failure, which is another reason to avoid it in favor of febuxostat.

Wait, but I should check if there are any other factors. For example, in severe renal impairment, febuxostat's dosage might still need adjustment, but generally, it's considered safer than allopurinol in this context. Also, the clinical pearl here is that febuxostat is the preferred xanthine oxidase inhibitor for patients with renal impairment because it's not nephrotoxic and doesn't require dose adjustment as much as allopurinol. So the correct answer should be febuxostat.

**Core Concept**
Chronic gout management in renal impairment prioritizes drugs with minimal nephrotoxicity and predictable metabolism. Xanthine oxidase inhibitors (XOIs) like **febuxostat** are preferred over **allopurinol** in renal dysfunction due to reduced reliance on renal excretion.

**Why the Correct Answer is Right**
Febuxostat inhibits xanthine oxidase, reducing uric acid synthesis. It is metabolized hepatically and excreted via both feces and urine, making it less dependent on renal function than allopurinol. This pharmacokinetic profile avoids the

✓ Correct Answer: C. Allopurinol